hackint0sh/temp-data huggingface dataset:
protocolSection identificationModule nctId: NCT06375330, orgStudyIdInfo id: Poli.01, briefTitle: Clinical Efficacy of Polynucleotides TMJ Injections Compared to Physiotherapy., statusModule overallStatus: COMPLETED, startDateStruct date: 2023-04-18, primaryCompletionDateStruct date: 2024-01-08, completionDateStruct date: 2024-04-08, studyFirstPostDateStruct date: 2024-04-19, lastUpdatePostDateStruct date: 2024-04-19, sponsorCollaboratorsModule leadSponsor name: Sidoti & Tartaglia Srl, class: OTHER, descriptionModule briefSummary: The main objective of the present study is the evaluation of the clinical efficacy of the intra-articular administration of polynucleotides in association with hyaluronic acid in the improvement of the subjective and objective manifestations of arthrosis of the temporomandibular joint compared to normal clinical management which involves Physiotherapy., conditionsModule conditions: TMJ Disease, conditions: TMJ Pain, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: TREATMENT, maskingInfo masking: SINGLE, whoMasked: OUTCOMES_ASSESSOR, enrollmentInfo count: 60, type: ACTUAL, armsInterventionsModule interventions name: PoliArt, outcomesModule primaryOutcomes measure: Maximum mouth opening, secondaryOutcomes measure: Lateral movements improvements, secondaryOutcomes measure: Pain assessment, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: UOC di Chirurgia Maxillo-Facciale e Odontostomatologia della Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, city: Milan, state: MI, zip: 20122, country: Italy, geoPoint lat: 45.46427, lon: 9.18951, hasResults: False
protocolSection identificationModule nctId: NCT06375317, orgStudyIdInfo id: HCC-HAIC-001, briefTitle: HAIC Combined With PD-L1 Plus Regorafenib in the Treatment of Advanced Hepatocellular Carcinoma After Immunotherapy Failure, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-04-30, primaryCompletionDateStruct date: 2026-04-30, completionDateStruct date: 2026-10-30, studyFirstPostDateStruct date: 2024-04-19, lastUpdatePostDateStruct date: 2024-04-19, sponsorCollaboratorsModule leadSponsor name: Yehua Shen, class: OTHER, descriptionModule briefSummary: For patients with advanced liver cancer who have progressed after first-line targeted and immunotherapy, there is currently no standard treatment regimen for second-line therapy. this study aims to explore the efficacy and safety of HAIC combined with PD-L1 and Regorafenib in patients with advanced liver cancer who have failed immunotherapy, not only providing new treatment options for second-line therapy of liver cancer, but also laying the foundation for research on the combination of HAIC and PD-L1 inhibitors plus Regorafenib, which has significant scientific research significance and clinical value., conditionsModule conditions: HCC - Hepatocellular Carcinoma, designModule studyType: INTERVENTIONAL, phases: PHASE2, designInfo allocation: NA, interventionModel: SINGLE_GROUP, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 42, type: ESTIMATED, armsInterventionsModule interventions name: PD-L1 inhibitor: Adebrelimab Injection；Regorafenib Tablets, outcomesModule primaryOutcomes measure: Objective Response Rate, secondaryOutcomes measure: Disease Control Rate (DCR), secondaryOutcomes measure: Progression-Free Survival (PFS), secondaryOutcomes measure: Overall Survival (OS), eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule, hasResults: False
protocolSection identificationModule nctId: NCT06375304, orgStudyIdInfo id: MP-37-2024-10384, briefTitle: The Antiretroviral Speed Access Program Switch (ASAP-Switch) Study, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-05-01, primaryCompletionDateStruct date: 2026-06-01, completionDateStruct date: 2027-05-01, studyFirstPostDateStruct date: 2024-04-19, lastUpdatePostDateStruct date: 2024-04-19, sponsorCollaboratorsModule leadSponsor name: McGill University Health Centre/Research Institute of the McGill University Health Centre, class: OTHER, descriptionModule briefSummary: This project builds on our experience with the ASAP Study (McGill University Health Centre research ethics board: MP-37-2020-4911). The goal of this study is to better understand the experience of migrant people with Human Immunodeficiency Virus (HIV) of having their treatment switched to Bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF). In other words, the investigators want to evaluate how feasible and acceptable this switch is, and how participants will take B/F/TAF (fidelity) and remain on it. The investigators also want to know more about migrant people with HIV's experience of care; namely, how often they see their HIV specialist or other healthcare professionals, and their healthcare coverage (the type of insurance that they have)., conditionsModule conditions: HIV Infections, designModule studyType: INTERVENTIONAL, phases: PHASE4, designInfo allocation: NA, interventionModel: SINGLE_GROUP, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 50, type: ESTIMATED, armsInterventionsModule interventions name: B/F/TAF, outcomesModule primaryOutcomes measure: Feasibility of the switch, primaryOutcomes measure: Acceptability, primaryOutcomes measure: acceptability of the regimen, primaryOutcomes measure: Acceptability of the intervention, primaryOutcomes measure: Fidelity, secondaryOutcomes measure: ART initiation (HIV care cascade milestones), secondaryOutcomes measure: Viral suppression (HIV care cascade milestones), secondaryOutcomes measure: Retention in HIV care (HIV care cascade milestones), secondaryOutcomes measure: consultations at the study site (Nature of clinical pathways), secondaryOutcomes measure: consultations at other care centres or organizations (Nature of clinical pathways), secondaryOutcomes measure: healthcare coverage, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Research Institute of the McGill University Health Centre, city: Montréal, state: Quebec, zip: H4A3T2, country: Canada, contacts name: Bertrand Lebouché, MD, PhD, role: CONTACT, phone: +1-514-843-2090, email: bertrand.lebouche@mcgill.ca, contacts name: Ashkan Baradaran, MD, MSc, role: CONTACT, phone: +1 514-863-4468, email: ashkan.baradaran@muhc.mcgill.ca, geoPoint lat: 45.50884, lon: -73.58781, hasResults: False
protocolSection identificationModule nctId: NCT06375291, orgStudyIdInfo id: MersinTRHpregcts, briefTitle: Pregnancy-Related Carpal Tunnel Syndrome Treatment, statusModule overallStatus: COMPLETED, startDateStruct date: 2021-01-01, primaryCompletionDateStruct date: 2023-12-31, completionDateStruct date: 2024-03-31, studyFirstPostDateStruct date: 2024-04-19, lastUpdatePostDateStruct date: 2024-04-22, sponsorCollaboratorsModule leadSponsor name: Mersin Training and Research Hospital, class: OTHER_GOV, descriptionModule briefSummary: The current retrospective study aimed to compare the effectiveness of local steroid injection plus splinting with that of local steroid injection or splinting alone. To assess the primary outcome, The Boston Carpal Tunnel Symptom Severity Scale was used. The secondary aim was the efficacy of the treatment on the patient's function severity and depression assessed by The Boston Carpal Tunnel Symptom Function Scale Edinburgh Depression Scale., conditionsModule conditions: Carpal Tunnel Syndrome Pregnancy, designModule studyType: OBSERVATIONAL, designInfo observationalModel: COHORT, timePerspective: RETROSPECTIVE, enrollmentInfo count: 45, type: ACTUAL, armsInterventionsModule interventions name: splint /steroid injection/both, outcomesModule primaryOutcomes measure: Symptom severity, secondaryOutcomes measure: function severity, secondaryOutcomes measure: pregnancy and postpartum depression, eligibilityModule sex: FEMALE, minimumAge: 18 Years, maximumAge: 35 Years, stdAges: ADULT, contactsLocationsModule locations facility: Suna Aşkın Turan, city: Mersin, state: Yenişehir, zip: 33020, country: Turkey, geoPoint lat: 36.79526, lon: 34.61792, hasResults: False
protocolSection identificationModule nctId: NCT06375278, orgStudyIdInfo id: DC019586, secondaryIdInfos id: 5R44DC019586, type: NIH, link: https://reporter.nih.gov/quickSearch/5R44DC019586, briefTitle: Investigation of a Device to Deliver Intra-Operative Therapeutic Hypothermia for Hearing Preservation in Cochlear Implantation, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-06-01, primaryCompletionDateStruct date: 2025-12-31, completionDateStruct date: 2026-03-31, studyFirstPostDateStruct date: 2024-04-19, lastUpdatePostDateStruct date: 2024-04-19, sponsorCollaboratorsModule leadSponsor name: Restorear Devices LLC, class: INDUSTRY, collaborators name: University of Miami, collaborators name: National Institute on Deafness and Other Communication Disorders (NIDCD), descriptionModule briefSummary: The goal of this interventional clinical study is to investigate the use of mild therapeutic hypothermia for preservation of residual hearing in cochlear implant surgery. The main questions the trial aims to answer are:1. Is mild therapeutic hypothermia safe for use during cochlear implantation?2. Is mild therapeutic hypothermia effective at preserving residual hearing after cochlear implantation?Participants will receive mild therapeutic hypothermia therapy during cochlear implant surgery. Researchers will compare results from those receiving the therapy to those from a control group (individuals receiving no therapy)., conditionsModule conditions: Cochlear Implants, conditions: Cochlear Implantation, conditions: Hearing Loss, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: PREVENTION, maskingInfo masking: DOUBLE, whoMasked: PARTICIPANT, whoMasked: OUTCOMES_ASSESSOR, enrollmentInfo count: 54, type: ESTIMATED, armsInterventionsModule interventions name: Intra-Ear Canal Cooling Catheter, interventions name: Intra-Ear Canal Cooling Catheter (Sham), outcomesModule primaryOutcomes measure: Cochlear Implant (CI) Device Performance Following Hypothermia Treatment, primaryOutcomes measure: Residual Hearing, secondaryOutcomes measure: Electrophysiological Impedance, secondaryOutcomes measure: Electrically Evoked Compound Action Potential (ECAP), eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: University of Miami, city: Miami, state: Florida, zip: 33136, country: United States, geoPoint lat: 25.77427, lon: -80.19366, hasResults: False
protocolSection identificationModule nctId: NCT06375265, orgStudyIdInfo id: 2024P000780-1, briefTitle: Digital Sleep Optimization for Brain Health Outcomes in Older Surgical Patients, acronym: SLEEP-BOOST, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-10-31, primaryCompletionDateStruct date: 2026-05-31, completionDateStruct date: 2026-08-31, studyFirstPostDateStruct date: 2024-04-19, lastUpdatePostDateStruct date: 2024-04-19, sponsorCollaboratorsModule leadSponsor name: Massachusetts General Hospital, class: OTHER, descriptionModule briefSummary: The Sleep Optimization for Brain Health Outcomes in Older Surgical Patients (SLEEP-BOOST) is a pilot randomized, controlled, singled-blinded (participant) trial in major orthopedic joint surgery patients that will build on a previously clinically tested cognitive behavioral therapy for insomnia (CBT-I) mobile application paired with a wearable device (wrist actigraphy)., conditionsModule conditions: Insomnia, conditions: Postoperative Delirium, conditions: Delayed Neurocognitive Recovery, conditions: Postoperative Neurocognitive Disorder, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 50, type: ESTIMATED, armsInterventionsModule interventions name: digital Cognitive Behavioral Therapy for Insomnia (dCBT-I), interventions name: Sleep Health Education, outcomesModule primaryOutcomes measure: Adherence, primaryOutcomes measure: Insomnia Severity, secondaryOutcomes measure: Sleep Diary Completion, secondaryOutcomes measure: Homework Completion, secondaryOutcomes measure: Utility, secondaryOutcomes measure: Satisfaction with intervention, secondaryOutcomes measure: Cognition, secondaryOutcomes measure: Pain severity, secondaryOutcomes measure: Mood, secondaryOutcomes measure: Anxiety, secondaryOutcomes measure: Function, secondaryOutcomes measure: Postoperative Delirium Incidence, secondaryOutcomes measure: Postoperative Delirium Severity, secondaryOutcomes measure: Delayed Neurocognitive Recovery, secondaryOutcomes measure: Postoperative Neurocognitive Disorders (NCD), secondaryOutcomes measure: Sleep Efficiency, otherOutcomes measure: Circadian Rest-Activity Rhythms, eligibilityModule sex: ALL, minimumAge: 65 Years, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Massachusetts General Hospital, city: Boston, state: Massachusetts, zip: 02114, country: United States, geoPoint lat: 42.35843, lon: -71.05977, hasResults: False
protocolSection identificationModule nctId: NCT06375252, orgStudyIdInfo id: sbughfyaseminozkan1985, briefTitle: Evaluation of Central Jugular Vein Catheter Lumen Holder Design and Ergonomic Use, acronym: CJVClumen, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-04-19, primaryCompletionDateStruct date: 2024-05-16, completionDateStruct date: 2024-05-30, studyFirstPostDateStruct date: 2024-04-19, lastUpdatePostDateStruct date: 2024-04-19, sponsorCollaboratorsModule leadSponsor name: Saglik Bilimleri Universitesi, class: OTHER, descriptionModule briefSummary: The aim of this study was to evaluate the design and ergonomic use of central jugular vein catheter lumen holder., conditionsModule conditions: Central Venous Catheterization, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: CROSSOVER, primaryPurpose: HEALTH_SERVICES_RESEARCH, maskingInfo masking: NONE, enrollmentInfo count: 40, type: ESTIMATED, armsInterventionsModule interventions name: Central Jugular Vein Catheter Lumen Holder Apparatus, outcomesModule primaryOutcomes measure: demographic information, secondaryOutcomes measure: comfort effect, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 65 Years, stdAges: ADULT, stdAges: OLDER_ADULT, hasResults: False
protocolSection identificationModule nctId: NCT06375239, orgStudyIdInfo id: RTx-VRAI-NHS01, briefTitle: Observational Study to Assess Endpoint Operational Feasibility & Measurement Properties in Retinitis Pigmentosa Patients, statusModule overallStatus: RECRUITING, startDateStruct date: 2024-04-05, primaryCompletionDateStruct date: 2026-04-30, completionDateStruct date: 2026-04-30, studyFirstPostDateStruct date: 2024-04-19, lastUpdatePostDateStruct date: 2024-04-19, sponsorCollaboratorsModule leadSponsor name: Ray Therapeutics, Inc., class: INDUSTRY, collaborators name: The Vision Research and Assessment Institute (VRAI), descriptionModule briefSummary: RayTx established The Vision Research and Assessment Institute (VRAI) with the express purpose of serving as a testing facility for efficacy endpoints for patients with Low Vision. The mission of the VRAI is to enable the highest quality, standardized efficacy testing of patients with visual impairment to be performed by expert clinicians in an optimized environment. The proposed assessments or testing modalities to be evaluated in this non-interventional study are published in some capacity, and some of these publications already include patients with severe-to-profound vision loss from retinitis pigmentosa and other inherited retinal diseases., conditionsModule conditions: Retinitis Pigmentosa, designModule studyType: OBSERVATIONAL, designInfo observationalModel: COHORT, timePerspective: PROSPECTIVE, enrollmentInfo count: 40, type: ESTIMATED, armsInterventionsModule, outcomesModule primaryOutcomes measure: Operational feasibility of testing severe to profound vision impaired patients with RP on a battery of visual assessments, secondaryOutcomes measure: To quantify patient-based measurement properties of each test modality (for the purposes of endpoint qualification), secondaryOutcomes measure: To quantify assessor-based measurement properties of each test modality (for the purposes of endpoint qualification), eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Vision Research and Assessment Institute, status: RECRUITING, city: Irvine, state: California, zip: 92612, country: United States, contacts name: Shawn Yu, OD, role: CONTACT, phone: 949-264-3793, email: info@vr-ai.com, geoPoint lat: 33.66946, lon: -117.82311, hasResults: False
protocolSection identificationModule nctId: NCT06375226, orgStudyIdInfo id: 2023.17, secondaryIdInfos id: 2023.0871, type: OTHER, domain: METC Amsterdam UMC, briefTitle: Autism and Attachment. An Explorative Study of Attachment Styles in Autistic Adults., acronym: ASDA, statusModule overallStatus: RECRUITING, startDateStruct date: 2024-03-01, primaryCompletionDateStruct date: 2025-04-01, completionDateStruct date: 2025-04-01, studyFirstPostDateStruct date: 2024-04-19, lastUpdatePostDateStruct date: 2024-04-23, sponsorCollaboratorsModule leadSponsor name: Parnassia Groep, class: OTHER, descriptionModule briefSummary: The present study examines the relationship between attachment and autism spectrum disorder (ASD) in adults., conditionsModule conditions: Autism Spectrum Disorder, designModule studyType: OBSERVATIONAL, designInfo observationalModel: OTHER, timePerspective: CROSS_SECTIONAL, enrollmentInfo count: 60, type: ESTIMATED, outcomesModule primaryOutcomes measure: The Social Responsiveness Scale - Adult version (SRS-A), primaryOutcomes measure: The Attachment Styles Questionnaire (ASQ), primaryOutcomes measure: Experiences in Close Relationships - Revised questionnaire (ECR-r), eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 65 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: ParnassiaGroep Antes, status: RECRUITING, city: Rotterdam, state: Zuid-Holland, zip: 3083 AK, country: Netherlands, contacts name: Stephanie Bohnen, MSc, role: CONTACT, phone: +31653386139, email: s.bohnen@anteszorg.nl, contacts name: Richard Vuijk, Dr., role: CONTACT, phone: +31883585428, email: r.vuijk@anteszorg.nl, geoPoint lat: 51.9225, lon: 4.47917, documentSection largeDocumentModule largeDocs typeAbbrev: Prot_SAP, hasProtocol: True, hasSap: True, hasIcf: False, label: Study Protocol and Statistical Analysis Plan, date: 2023-10-19, uploadDate: 2024-03-29T08:28, filename: Prot_SAP_000.pdf, size: 287252, hasResults: False
protocolSection identificationModule nctId: NCT06375187, orgStudyIdInfo id: GC203 TIL-ST-Ⅰ, briefTitle: Engineering Tumor Infiltrating Lymphocytes Injection (GC203 TIL) for the Treatment of Advanced Malignant Solid Tumors, acronym: KUNLUN-001, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-05-01, primaryCompletionDateStruct date: 2025-11-01, completionDateStruct date: 2027-05-01, studyFirstPostDateStruct date: 2024-04-19, lastUpdatePostDateStruct date: 2024-04-23, sponsorCollaboratorsModule leadSponsor name: Shanghai Juncell Therapeutics, class: INDUSTRY, descriptionModule briefSummary: A clinical trial to assess the safety and efficacy of engineered Tumor Infiltrating Lymphocytes (TIL) for the treatment of Advanced Malignant Solid Tumors, conditionsModule conditions: Solid Tumor, conditions: Gynecologic Cancer, conditions: Breast Cancer, conditions: Gastrointestinal Cancer, conditions: Lung Cancer, designModule studyType: INTERVENTIONAL, phases: PHASE1, designInfo allocation: NA, interventionModel: SINGLE_GROUP, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 18, type: ESTIMATED, armsInterventionsModule interventions name: Engineering Tumor Infiltrating Lymphocytes, outcomesModule primaryOutcomes measure: Maximal Tolerance Dose, primaryOutcomes measure: Dose Limiting Toxicity, primaryOutcomes measure: Adverse Events, secondaryOutcomes measure: Objective Response Rate, secondaryOutcomes measure: Duration of Response, secondaryOutcomes measure: Disease Control Rate, secondaryOutcomes measure: Progression-Free Survival, secondaryOutcomes measure: Overall Survival, secondaryOutcomes measure: Quality of Life Assessment, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 75 Years, stdAges: ADULT, stdAges: OLDER_ADULT, hasResults: False
protocolSection identificationModule nctId: NCT06375174, orgStudyIdInfo id: NSISTRCR_2202, briefTitle: PRECISE (PERFUSION IMAGING TO IDENTIFY POSTERIOR CIRCULATION CANDIDATES FOR THROMBECTOMY), acronym: SWISS-PRECISE, statusModule overallStatus: ACTIVE_NOT_RECRUITING, startDateStruct date: 2024-01-09, primaryCompletionDateStruct date: 2026-02-28, completionDateStruct date: 2026-02-28, studyFirstPostDateStruct date: 2024-04-19, lastUpdatePostDateStruct date: 2024-04-19, sponsorCollaboratorsModule leadSponsor name: Dr. med. Carlo Cereda, class: OTHER_GOV, descriptionModule briefSummary: We hypothesize that patients with a favorable Critical Area Perfusion Score (CAPS≤3) on cerebral perfusion imaging will have a favorable response to revascularization by thrombectomy and that patients with a CAPS\>3 will not, conditionsModule conditions: Posterior Circulation Acute Ischemic Stroke Due to Large Vessel Occlusion of the Vertebral or Basilar Artery Needing Endovascular Thrombectomy, designModule studyType: OBSERVATIONAL, designInfo observationalModel: CASE_ONLY, timePerspective: PROSPECTIVE, enrollmentInfo count: 120, type: ESTIMATED, armsInterventionsModule interventions name: Thrombectomy, outcomesModule primaryOutcomes measure: mRS score, eligibilityModule sex: ALL, stdAges: CHILD, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Neurocenter of Southern Switzerland, Ospedale Civico, city: Lugano, state: Ticino, zip: CH-6900, country: Switzerland, geoPoint lat: 46.01008, lon: 8.96004, hasResults: False
protocolSection identificationModule nctId: NCT06375161, orgStudyIdInfo id: CD19-CN-A6, briefTitle: Anti-CD19-CAR-T Cells in Relapsed/Refractory B-cell Tumor Patients., statusModule overallStatus: RECRUITING, startDateStruct date: 2023-12-11, primaryCompletionDateStruct date: 2025-12-10, completionDateStruct date: 2039-12-10, studyFirstPostDateStruct date: 2024-04-19, lastUpdatePostDateStruct date: 2024-04-19, sponsorCollaboratorsModule leadSponsor name: Shanghai Tongji Hospital, Tongji University School of Medicine, class: OTHER, descriptionModule briefSummary: This study is a single-center, open-label, single-dose clinical trial of anti-CD19-CAR-T cell therapy in relapsed/refractory B-cell tumor patients after Qinglin pre-treatment.In this study phase, a traditional "3+3" trial design is employed for dose escalation., conditionsModule conditions: B Cell Malignancies, designModule studyType: INTERVENTIONAL, phases: EARLY_PHASE1, designInfo allocation: NA, interventionModel: SINGLE_GROUP, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 12, type: ESTIMATED, armsInterventionsModule interventions name: anti-CD19-CAR-T cells, outcomesModule primaryOutcomes measure: Incidence of dose-limiting toxicity, eligibilityModule sex: ALL, minimumAge: 18 Weeks, maximumAge: 70 Weeks, stdAges: CHILD, contactsLocationsModule locations facility: Shanghai Tongji Hospital, status: RECRUITING, city: Shanghai, state: Shanghai, zip: 200333, country: China, contacts name: Aibin Liang, role: CONTACT, phone: +8618601670600, email: lab7182@tongji.edu.cn, contacts name: Ping LI, role: CONTACT, phone: +86 135 6418 1131, email: lilyforever@126.com, geoPoint lat: 31.22222, lon: 121.45806, hasResults: False